Zhenfeng Duan

Author PubWeight™ 51.62‹?›

Top papers

Rank Title Journal Year PubWeight™‹?›
1 Interleukin-6 signaling pathway in targeted therapy for cancer. Cancer Treat Rev 2012 2.82
2 Phase 1 study of oral abexinostat, a histone deacetylase inhibitor, in combination with doxorubicin in patients with metastatic sarcoma. Cancer 2014 1.43
3 MicroRNA Involvement in Osteosarcoma. Sarcoma 2012 1.38
4 Modulation of intracellular ceramide using polymeric nanoparticles to overcome multidrug resistance in cancer. Cancer Res 2007 1.34
5 Recurrent chromosomal copy number alterations in sporadic chordomas. PLoS One 2011 1.24
6 Inhibition of ABCB1 (MDR1) expression by an siRNA nanoparticulate delivery system to overcome drug resistance in osteosarcoma. PLoS One 2010 1.16
7 Molecular description of evolving paclitaxel resistance in the SKOV-3 human ovarian carcinoma cell line. Cancer Res 2003 1.15
8 High-throughput genotyping in osteosarcoma identifies multiple mutations in phosphoinositide-3-kinase and other oncogenes. Cancer 2011 1.13
9 Modulation of drug resistance in ovarian adenocarcinoma by enhancing intracellular ceramide using tamoxifen-loaded biodegradable polymeric nanoparticles. Clin Cancer Res 2008 1.12
10 Molecular distinction of chondrosarcoma from chondroblastic osteosarcoma through IDH1/2 mutations. Am J Surg Pathol 2013 1.08
11 A novel target for treatment of chordoma: signal transducers and activators of transcription 3. Mol Cancer Ther 2009 1.07
12 Development of EGFR-targeted polymer blend nanocarriers for combination paclitaxel/lonidamine delivery to treat multi-drug resistance in human breast and ovarian tumor cells. Mol Pharm 2010 1.07
13 Effects of siltuximab on the IL-6-induced signaling pathway in ovarian cancer. Clin Cancer Res 2010 1.06
14 Doxorubicin loaded Polymeric Nanoparticulate Delivery System to overcome drug resistance in osteosarcoma. BMC Cancer 2009 1.05
15 ROCK1 as a potential therapeutic target in osteosarcoma. J Orthop Res 2011 1.04
16 Paclitaxel and ceramide co-administration in biodegradable polymeric nanoparticulate delivery system to overcome drug resistance in ovarian cancer. Int J Cancer 2007 1.04
17 Activation of signal transducer and activator of transcription 3 (Stat3) pathway in osteosarcoma cells and overexpression of phosphorylated-Stat3 correlates with poor prognosis. J Orthop Res 2010 1.03
18 Role of hypoxia and glycolysis in the development of multi-drug resistance in human tumor cells and the establishment of an orthotopic multi-drug resistant tumor model in nude mice using hypoxic pre-conditioning. Cancer Cell Int 2011 1.02
19 Histone deacetylase inhibitor (HDACI) PCI-24781 potentiates cytotoxic effects of doxorubicin in bone sarcoma cells. Cancer Chemother Pharmacol 2010 1.01
20 The kinase Mirk is a potential therapeutic target in osteosarcoma. Carcinogenesis 2009 1.01
21 Oleanane triterpenoid CDDO-Me induces apoptosis in multidrug resistant osteosarcoma cells through inhibition of Stat3 pathway. BMC Cancer 2010 1.00
22 Therapeutic efficacy and safety of paclitaxel/lonidamine loaded EGFR-targeted nanoparticles for the treatment of multi-drug resistant cancer. PLoS One 2011 1.00
23 Characterization and analysis of human chordoma cell lines. Spine (Phila Pa 1976) 2010 0.97
24 Combination of PI3K/mTOR inhibition demonstrates efficacy in human chordoma. Anticancer Res 2009 0.97
25 Hepsin colocalizes with desmosomes and induces progression of ovarian cancer in a mouse model. Int J Cancer 2008 0.95
26 Tissue microarray immunohistochemical detection of brachyury is not a prognostic indicator in chordoma. PLoS One 2013 0.95
27 Targeting hedgehog-GLI-2 pathway in osteosarcoma. J Orthop Res 2012 0.92
28 MicroRNA-1 (miR-1) inhibits chordoma cell migration and invasion by targeting slug. J Orthop Res 2014 0.92
29 Augmentation of therapeutic efficacy in drug-resistant tumor models using ceramide coadministration in temporal-controlled polymer-blend nanoparticle delivery systems. AAPS J 2010 0.91
30 Establishment and characterization of a novel chordoma cell line: CH22. J Orthop Res 2012 0.89
31 Cyclin-dependent kinase 11 (CDK11) is crucial in the growth of liposarcoma cells. Cancer Lett 2013 0.89
32 Histone deacetylase inhibitor PCI-24781 enhances chemotherapy-induced apoptosis in multidrug-resistant sarcoma cell lines. Anticancer Res 2011 0.88
33 Biodistribution and pharmacokinetic analysis of Paclitaxel and ceramide administered in multifunctional polymer-blend nanoparticles in drug resistant breast cancer model. Mol Pharm 2008 0.88
34 Cluster of Differentiation 44 Targeted Hyaluronic Acid Based Nanoparticles for MDR1 siRNA Delivery to Overcome Drug Resistance in Ovarian Cancer. Pharm Res 2014 0.88
35 Inhibition of polo-like kinase 1 leads to the suppression of osteosarcoma cell growth in vitro and in vivo. Anticancer Drugs 2011 0.87
36 Cyclin G-associated kinase is necessary for osteosarcoma cell proliferation and receptor trafficking. Mol Cancer Ther 2010 0.87
37 Targeting CDK11 in osteosarcoma cells using the CRISPR-Cas9 system. J Orthop Res 2014 0.86
38 Taxol-resistance-associated gene-3 (TRAG-3/CSAG2) expression is predictive for clinical outcome in ovarian carcinoma patients. Virchows Arch 2007 0.86
39 beta tubulin mutations are rare in human ovarian carcinoma. Anticancer Res 2003 0.86
40 Lipid-functionalized dextran nanosystems to overcome multidrug resistance in cancer: a pilot study. Clin Orthop Relat Res 2013 0.85
41 Multidrug resistant osteosarcoma cell lines exhibit deficiency of GADD45alpha expression. Apoptosis 2009 0.85
42 BRAF mutation in 'sarcomas': a possible method to detect de-differentiated melanomas. Histopathology 2013 0.83
43 RAIDD expression is impaired in multidrug resistant osteosarcoma cell lines. Cancer Chemother Pharmacol 2009 0.82
44 Blockage of Stat3 with CDDO-Me inhibits tumor cell growth in chordoma. Spine (Phila Pa 1976) 2010 0.82
45 Multidrug resistance reversal agent, NSC77037, identified with a cell-based screening assay. J Biomol Screen 2010 0.82
46 Guanine nucleotide-binding protein 1 is one of the key molecules contributing to cancer cell radioresistance. Cancer Sci 2014 0.81
47 Proteomic profiling of chordoma. J Surg Oncol 2010 0.80
48 Nanodelivery systems for nucleic acid therapeutics in drug resistant tumors. Mol Pharm 2014 0.78
49 Nanoparticles: a promising modality in the treatment of sarcomas. Pharm Res 2010 0.78
50 Decreased expression and activation of Stat3 in severe preeclampsia. J Mol Histol 2015 0.77
51 Development of a new pre-vascularized tissue-engineered construct using pre-differentiated rADSCs, arteriovenous vascular bundle and porous nano-hydroxyapatide-polyamide 66 scaffold. BMC Musculoskelet Disord 2013 0.75
52 Microbubble embedded with upconversion nanoparticles as a bimodal contrast agent for fluorescence and ultrasound imaging. Nanotechnology 2015 0.75
53 Inkjet printing of upconversion nanoparticles for anti-counterfeit applications. Nanoscale 2015 0.75
54 Facial Layer-by-Layer Engineering of Upconversion Nanoparticles for Gene Delivery: Near-Infrared-Initiated Fluorescence Resonance Energy Transfer Tracking and Overcoming Drug Resistance in Ovarian Cancer. ACS Appl Mater Interfaces 2017 0.75
55 Three-dimensional (3D) culture in sarcoma research and the clinical significance. Biofabrication 2017 0.75
56 [Regulation of chondrosarcoma cell growth using synthesized hydrogels with different electric charges]. Sheng Wu Yi Xue Gong Cheng Xue Za Zhi 2013 0.75
57 Multiscale agent-based modelling of ovarian cancer progression under the stimulation of the STAT 3 pathway. Int J Data Min Bioinform 2014 0.75